Cocrystal Pharma Quote - COCP

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.9199

Bid

1.90

Ask

1.92

Volume

6,717

1.85 Day's Range 1.98

1.35 52 Week Range 3.26

Market Cap

19.533M

Previous Close

1.95

Open

1.85

Last Trade

100

1.9199

Last Trade Time

12:47:28

Financial Volume

US$ 12,585

VWAP

1.8736

Average Volume (3m)

50,931

Shares Outstanding

10,173,790

Dividend Yield

PE Ratio

-1.11

Earnings Per Share (EPS)

-1.77

Revenue

2.6M

Net Profit

-17.98M

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first... Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cocrystalpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Cocrystal Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker COCP. The last closing price for Cocrystal Pharma was US$1.95. Over the last year, Cocrystal Pharma shares have traded in a share price range of US$ 1.35 to US$ 3.26.

Cocrystal Pharma currently has 10,173,790 shares outstanding. The market capitalization of Cocrystal Pharma is US$19.84 million. Cocrystal Pharma has a price to earnings ratio (PE ratio) of -1.11.

Form 8-K - Current report

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human...

Form 8-K - Current report

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the...

Form 8-K - Current report

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.1299	7.25698324022	1.79	2.08	1.75	40963	1.87056918	CS
4	-0.1201	-5.88725490196	2.04	2.34	1.63	32339	2.00777704	CS
12	-0.1401	-6.80097087379	2.06	3.26	1.63	50931	2.27473604	CS
26	-0.0401	-2.04591836735	1.96	3.26	1.6	32097	2.1625121	CS
52	0.4899	34.2587412587	1.43	3.26	1.35	28895	2.11374736	CS
156	-4.3213	-69.2382875088	6.2412	7.5588	1.325	79078	4.14318841	CS
260	-7.6597	-79.9584533801	9.5796	49.2	1.325	2039484	18.93205991	CS

COCP - Frequently Asked Questions (FAQ)

What is the current Cocrystal Pharma share price?

The current share price of Cocrystal Pharma is US$ 1.9199

How many Cocrystal Pharma shares are in issue?

Cocrystal Pharma has 10,173,790 shares in issue

What is the market cap of Cocrystal Pharma?

The market capitalisation of Cocrystal Pharma is USD 19.84M

What is the 1 year trading range for Cocrystal Pharma share price?

Cocrystal Pharma has traded in the range of US$ 1.35 to US$ 3.26 during the past year

What is the PE ratio of Cocrystal Pharma?

The price to earnings ratio of Cocrystal Pharma is -1.11

What is the cash to sales ratio of Cocrystal Pharma?

The cash to sales ratio of Cocrystal Pharma is 7.71

What is the reporting currency for Cocrystal Pharma?

Cocrystal Pharma reports financial results in USD

What is the latest annual turnover for Cocrystal Pharma?

The latest annual turnover of Cocrystal Pharma is USD 2.6M

What is the latest annual profit for Cocrystal Pharma?

The latest annual profit of Cocrystal Pharma is USD -17.98M

What is the registered address of Cocrystal Pharma?

The registered address for Cocrystal Pharma is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Cocrystal Pharma website address?

The website address for Cocrystal Pharma is www.cocrystalpharma.com

Which industry sector does Cocrystal Pharma operate in?

Cocrystal Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
STECSantech Holdings Limited	US$ 1.9098 (193.68%)	109.32M
YYAIConnexa Sports Technologies Inc	US$ 1.2699 (98.39%)	125.5M
PEPGPepGen Inc	US$ 2.63 (91.97%)	102.24M
RETOReTo Eco Solutions Inc	US$ 0.72 (77.38%)	67.32M
GSUNGolden Sun Health Technology Group Ltd	US$ 3.78 (42.64%)	2.6M
THTarget Hospitality Corporation	US$ 5.01 (-46.47%)	9.43M
NKLANikola Corporation	US$ 0.2528 (-33.47%)	38.45M
CHSNChanson International Holding	US$ 0.2599 (-29.07%)	4.36M
STAIScanTech AI Systems Inc	US$ 2.335 (-29.03%)	3.52M
BOXLBoxlight Corporation	US$ 2.2224 (-28.31%)	471.33k
NVDANVIDIA Corporation	US$ 134.71 (0.21%)	156.39M
PLTRPalantir Technologies Inc	US$ 93.4476 (-7.80%)	136.68M
YYAIConnexa Sports Technologies Inc	US$ 1.2607 (96.95%)	127.48M
CNEYCN Energy Group Inc	US$ 0.2721 (11.24%)	111.08M
STECSantech Holdings Limited	US$ 1.90 (192.17%)	110.12M